ClinicalTrials.gg
RecruitingNCT06321250Updated Jul 9, 2024

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

A Phase 1 interventional study of JMKX003948 in Renal Cell Carcinoma Metastatic, sponsored by Jemincare. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 234 studies in Carcinoma, Renal Cell with a site in China — 111 open to participants now, 141 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Planned enrollment
84th of 189
80 · median 66
Started
2024
with 32 others
Phase 1
40 of 234
19 open now
Primary completion
2026-05
later than 44 of 140 live
Registered
132nd of 234
by date

Among the 234 studies in Carcinoma, Renal Cell with a site in China, this one is the 84th largest by planned enrollment of the 189 interventional ones that give a count, is one of 33 that started in 2024, is one of 40 in phase 1, reaches primary completion later than 44 of the 140 other live ones, and was the 132nd registered.

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

111 of the 234 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.

03

Conditions studied

  • Renal Cell Carcinoma Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has the ability to understand and willingness to sign a written form.
  2. Male or female from 18 years of age or older.
  3. confirmed locally advanced or clear cell renal cell carcinoma.
  4. Has at least one per v1.1.
  5. Has a of ≥ 12 weeks.
  6. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known active and/or cancerous meningitis.
  2. Has received any type of systemic anticancer monoclonal antibodies or other within 4 weeks prior to the first dose. Has received prior chemotherapy, targeted therapy, or other therapy within 2 weeks prior to the first dose.
  3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy.
  4. Has impaired heart function,or cerebrovascular and cardiovascular disease.
  5. Subjects with dysphagia or known drug absorption disorders.
  6. Has a history of any other within 5 years.
  7. Has severe oncological complications.
  8. Is currently participating in other clinical studies.
  9. Subjects with be unsuitable for participation in the trial evaluated by investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Subjects will be assigned to pre-specified dose level to determine MTD/MAD of JMKX003948. Each treatment cycle will be 21 days.

    Drug: JMKX003948

  • Experimental
    Dose Expansion

    Subjects will be assigned to the recommended dose level determined in dose escalation Phase. Each treatment cycle will be 21 days.

    Drug: JMKX003948

Interventions

  • DrugJMKX003948

    Subjects will receive JMKX003948 tablets until disease progression

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of participants with dose limiting toxicities (DLTs)

    Number of participants with DLTs

    Time frame: Up to 2 months

  2. Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with AEs/SAEs to characterize the safety and tolerability of JMKX003948.

    Time frame: Up to 2 years

  3. Dose Expansion: Objective Response Rate (ORR)

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 1 year

Secondary outcomes

  1. maximum plasma concentration (Cmax)

    Maximum observed concentration.

    Time frame: Up to 1 month

  2. maximum plasma concentration (Tmax)

    Time to reach maximum observed plasma concentration.

    Time frame: Up to 1 month

  3. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
  • Beijing Caancer Hospital
    Beijing, China
    Recruiting
    • Jun Guo, Master · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2026, 26 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 26 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Mar 20, 2024
StartActual
Mar 14, 2024
Primary completionEst.
May 31, 2026
CompletionEst.
Apr 30, 2027
Last update
Jul 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06321250
Lead sponsor
Jemincare
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Mar 14, 2024
Primary completion
May 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jul 9, 2024

Study contacts

Huihui Xiang
Contact
xianghuihui@jemincare.com
+86 15928607671
Jun Guo
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion